Reproductive Health Supplies Pricing in Nepal and Nicaragua:

Equity, Availability, and Affordability



Introduction

- Poor reproductive health (RH) contributes to overall disease burden.
- Availability of essential RH supplies is constrained by:
 - Insufficient resources
 - Insufficient commitment
 - Systems inefficiencies
- Price of RH medicines affects access for the poor.



Background

- WHO/UNFPA published: The Interagency List of Essential Medicines for Reproductive Health:
 - http://www.who.int/medicines/publications/essentialmedicines /WHO-PSM-PAR-2006.1.pdf
- PATH and JSI: adapted WHO/HAI essential medicine (EM) price measurement approach to RH medicines.
- PATH and JSI: piloted approach in Nicaragua and Nepal, with these research objectives:
 - Identify gaps in understanding of RH medicines pricing and availability.
 - Inform RH medicines policy and program development.



Research Questions

- How efficient are public and private procurement systems?
- What are the price components and their cumulative mark-up effect on patient prices?
- What is the difference between the prices of lowest- and highest-cost generic equivalents (brand premium)?
- How available and affordable are essential reproductive health medicines?



Approach

- Adapt WHO/HAI price measurement methodology for RH medicines.
 - MSH/WHO median reference prices: http://erc.msh.org/dmpguide
- Develop RH medicines product tracer list and adapt to each country.
- Convene country-based TAGs and train pharmacy students as data collectors.
- Gather and analyze price and availability data.
 - High- and low-priced generics.
 - Public and private sectors.
 - Multiple regions of Nicaragua and Nepal.
 - Combined 121 public, NGO, and private outlets.



Key Findings

- **Efficiency**: Public-sector procurement relatively efficient in both countries.
 - Large gap in private-sector procurement efficiency between the two countries.
- **Generics**: High-priced generics (HPG) vastly more expensive than low-priced generics (LPG).

Nepal (95%); Nicaragua (836%)

- Availability: Limited availability of essential RH medicines in both public and private sectors.
 - Combined (26% public; 39% public)




- Affordability: treatment costs (based on days' wages) higher in Nicaragua.
- Margins: Significant cumulative price margins; exceed government guidelines in Nepal.

>400% of procurement cost.




Procurement Efficiency: Sector Comparison





Patient Prices (all sectors)



*

RH Product Availability

Public-sector outlets:

- LPG availability 25% (Nicaragua) and 28% (Nepal)
- HPG availability <4%
- Private-sector outlets:
 - LPG availability 40%
 - HPG availability 28% (Nicaragua) and 14% (Nepal)




RH Product Availability

- Average availability of all (HPG and LPG) products across sectors: 21%, Nepal; 24%, Nicaragua.
- Availability Ranges:
 - 92% LPG male condoms in Nepal.
 - 100% LPG amoxicillin in the public sector in Nicaragua.
 - 2.0% LPG Oxytocin across all sectors in Nepal.
 - 0% LPG progestin-only minipill across all sectors in Nicaragua.



Product Affordability





Cumulative Price Margins

| Nepal | | | |
|-----------------------|----------------------------|------------------|-----------------------------------|
| ENTITY | PRICE COMPONENT | % Mark- up | Cumulative Price and Margin |
| International | CIF/CIP Index Price | 0% | 100.0 |
| HMG Nepal | Import Tax | 5% | 105.0 |
| Importer | Distribution Margin | 2.5% | 107.6 |
| Importer | Profit Margin | 4.5% | 112.5 |
| Wholesaler | Profit Margin | 8.5% | 122.0 |
| Retailer | Profit Margin | 16% | 141.6 |
| Cumulative Markup | | 37% | 42% |
| Final Retail Price | | | 141.6 |

Nicaragua

Ministry of Promotion, Industry and Commerce is responsible for enforcing pricing policies and regulations.

➢Importer and distributor margins (30 – 35%), retail (30 – 35%).




Cumulative Price Margins (Nepal): Select RH products





Nepal: How are the margins distributed?



| Margins as a component |
|------------------------|
| of price: |

| ➤Oxytocin – | 61% |
|-------------|-----|
|-------------|-----|

- ➤Ampicillin 72%
- ➤TT vaccine 25%

What is the proportion of that margin each actor is levying within the distribution system?



Conclusions & Next Steps

- Availability of essential RH medicine is low in both Nicaragua and Nepal.
 - Steps need to be taken to increase availability of essential RH products across sectors.
- Product margins in Nepal (profits, distribution, taxes) are leading to high retail costs of essential RH medicines that many cannot afford.
 - Drug control authorities should enforce existing regulations governing allowable margins.
- Public-sector and NGO programs should promote good-quality, lowpriced generic products.
- Expectations of commercial-sector supply of RH medicines must be tempered with data on affordability.
- Similar research is needed in additional countries to identify trends and inform planning and decision-making.



Jane Hutchings, PATH Raja Rao, JSI/DELIVER Jolene Beitz, PATH

www.path.org www.deliver.jsi.com

